Overview
- Eli Lilly and Insilico Medicine signed a global research and development deal that gives Lilly an exclusive worldwide license to a portfolio of preclinical oral drug programs.
- Insilico will receive $115 million upfront, with additional development, regulatory, and commercial milestones that could bring the total to about $2.75 billion, plus tiered royalties on future sales.
- The partners will combine Insilico’s AI platforms with Lilly’s clinical and disease-area expertise to identify and advance candidates across several therapeutic areas.
- Insilico’s CEO says the company has at least 28 AI-designed drug programs, with nearly half already in clinical testing.
- Insilico develops its AI in Canada and the Middle East but runs early preclinical work in China, which tracks with Lilly’s plan to invest $3 billion there over the next decade.